Development of anticancer drugs based on the hallmarks of tumor cells

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 3981-3995

  Bailón Moscoso, Natalia ^a,b   Romero Benavides, Juan Carlos ^b   Ostrosky Wegman, Patricia ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD TÉCNICA PARTICULAR DE LOJA   (Ecuador)

Author keywords

Cancer; Cancer cell hallmarks; Drug design

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG; TUMOR PROMOTER;

ANGIOGENESIS; APOPTOSIS; CANCER GENETICS; CANCER INHIBITION; CELL DEATH; CELL ENERGY; DNA REPLICATION; DRUG DEVELOPMENT; DRUG MECHANISM; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; IMMUNE DYSREGULATION; IMMUNOMODULATION; INFLAMMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR INVASION; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; DRUG DISCOVERY; GENOMIC INSTABILITY; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84902958282     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1649-y     Document Type: Review

References (185)

1. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006;2:689-700. (Pubitemid 44764211)
2. Eastman A, Perez R. New targets and challenges in the molecular therapeutics of cancer. Br J Clin Pharmacol. 2006;62:5-14. (Pubitemid 44195238)
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
5. J.A. Engelman. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Cancer. 9 (2009).
6. Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, et al. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal. 2009;2:ra2.
7. Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7:1851-63.
8. Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012;319:1-7.
9. S. Pyndiah, S. Tanida, K.M. Ahmed, E.K. Cassimere, C. Choe, D. Sakamuro. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci. Signal. 4 (2011) ra19.
10. Larsson L-G, Henriksson MA. The yin and yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res. 2010;316:1429-37.
11. Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer Lett. 2003;197:125-30. (Pubitemid 36860001)
12. Lee MO, Han SY, Jiang S, Park JH, Kim SJ. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem Pharmacol. 2000;59:485-96. (Pubitemid 30045587)
13. Sarkar SA, Sharma RP. Expression of c-Myc and other apoptosis-related genes in Swiss Webster mouse fetuses after maternal exposure to all trans-retinoic acid. Reprod Toxicol. 2002;16:245-52. (Pubitemid 34966262)
14. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Morse EM, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067-73.
15. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904-17.
16. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524-8.
17. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-7.
18. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36:131-49. (Pubitemid 36808270)
19. Malumbres M, Barbacid M. Cell cycle. CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153-66.
20. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2:910-7. (Pubitemid 37328892)
21. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547-66.
22. Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 2005;5:366-73. (Pubitemid 40932038)
23. Woyach JA, Lozanski G, Ruppert AS, Lozanski A, Blum KA, Jones JA, et al. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia. 2012;26:1442-4.
24. Cirillo D, Pentimalli F, Giordano A. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors. Curr Med Chem. 2011;18:2854-66.
25. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3-11.
26. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-62.
27. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516. (Pubitemid 46911891)
28. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876-85. (Pubitemid 41746032)
29. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis. 2001;6:191-7. (Pubitemid 32423728)
30. Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol. 2009;625:63-72.
31. Ghobrial I, Witzig T, Adjei A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178-94. (Pubitemid 40826487)
32. van Geelen CM, Pennarun B, Le PT, de Vries EG, de Jong S. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer. 2011;11:39.
33. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-6.
34. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer. 2009;9:724-37.
35. Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 2006;13:921-6.
36. Lu P, Yang X, Huang Y, Lu Z, Miao Z, Liang Q, et al. Antitumor activity of a combination of rAd2p53 adenoviral gene therapy and radiotherapy in esophageal carcinoma. Cell Biochem Biophys. 2011;59:147-52.
37. Partridge M, Costea DE, Huang X. The changing face of p53 in head and neck cancer. Int J Oral Maxillofac Surg. 2007;36:1123-38. (Pubitemid 350138394)
38. Tovar C, Rosinski J, Filipovic Z. From the cover: small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Med Sci. 2006;103:188-1893.
39. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005;12 Suppl 1:942-61. (Pubitemid 41030608)
40. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106:408-18. (Pubitemid 40981231)
41. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-8. (Pubitemid 38174664)
42. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8:121-32. (Pubitemid 351161322)
43. Reed JC. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 2006;13:1378-86. (Pubitemid 44057473)
44. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989-1000.
45. Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res. 2007;13:7254-63.
46. M.H. Kang, C.P. Reynolds. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy targeting mitochondrial apoptotic pathways. Clin. Cancer Res. (2009) 1126-1132.
47. Hann CL, Daniel VC. E. a Sugar, I. Dobromilskaya, S.C. Murphy, L. Cope, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68:2321-8. (Pubitemid 351521806)
48. Kabore AF, Johnston JB, Gibson SB. Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr Cancer Drug Targets. 2004;4:147-63. (Pubitemid 38332553)
49. D'Amelio M, Tino E, Cecconi F. The apoptosome: emerging insights and new potential targets for drug design. Pharm Res. 2008;25:740-51.
50. Yang J-Y, Michod D, Walicki J, Widmann C. Surviving the kiss of death. Biochem Pharmacol. 2004;68:1027-31. (Pubitemid 39094266)
51. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61-70.
52. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anticancer therapy. Cancer Treat Rev. 2009;35:553-62.
53. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14:120-8.
54. Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013;332:225-8.
55. R. Arora, M. Shuda, A. Guastafierro, H. Feng, T. Toptan, Y. Tolstov, et al. Survivin is a therapeutic target in Merkel cell carcinoma. Sci. Transl. Med. 4 (2012) 133ra56.
56. Liu B, Cheng Y, Liu Q, Bao J, Yang J-M. Autophagic pathways as new targets for cancer drug development. Acta Pharmacol Sin. 2010;31:1154-64.
57. K.-D. Yu, Z.-M. Shao. The two faces of autophagy and the pathological underestimation of DCIS. Nat. Rev. Cancer. 11 (2011) 618; author reply 618.
58. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R, et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 2009;16:87-93.
59. Liu B, Wen X, Cheng Y. Survival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer. Cell Death Dis. 2013;4:e892.
60. Kubisch J, Türei D, Földvári-Nagy L. Z. a Dunai, L. Zsákai, M. Varga, et al. Complex regulation of autophagy in cancer-integrated approaches to discover the networks that hold a double-edged sword. Semin Cancer Biol. 2013;23:252-61.
61. Hayflick L. The strategy of senescence. Gerontol. 1974;14:37-45.
62. Bodnar AG, Ouellette M, Frolkis M, Holt S, Chiu C, Morin G, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349-52. (Pubitemid 28063364)
63. Guittat L, Alberti P, Gomez D, De Cian A, Pennarun G, Lemarteleur T, et al. Targeting human telomerase for cancer therapeutics. Cytotechnology. 2004;45:75-90. (Pubitemid 40568825)
64. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008;8:167-79. (Pubitemid 351305939)
65. Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology. 2005;42:1127-36. (Pubitemid 43112680)
66. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat. 2006;96:73-81.
67. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer. 2008;98:677-83. (Pubitemid 351272604)
68. Weiner L, Surana R, Wang S. Antibodies and cancer therapy: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317-27.
69. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2012;5:444-56.
70. Herbert BS. Disruption of telomere homeostasis as a new cancer treatment strategy. Memo - Mag. Eur Med Oncol. 2009;2:21-4.
71. Bochman ML, Paeschke K. V. a Zakian. DNA secondary structures: stability and function of G-quadruplex structures. Nat Rev Genet. 2012;13:770-80.
72. Kim M-Y, Vankayalapati H, Shin-ya K, Wierzba K, Hurley LH. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J Am Chem Soc. 2002;124:2098-9. (Pubitemid 34267081)
73. Burger AM, Dai F, Schultes CM, Reszka AP, Moore MJ. J. a Double, et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005;65:1489-96. (Pubitemid 40270178)
74. Leonetti C, Scarsella M, Riggio G, Rizzo A, Salvati E, D'Incalci M, et al. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin Cancer Res. 2008;14:7284-91.
75. Chen Y, Qu K, Zhao C, Wu L, Ren J, Wang J, et al. Insights into the biomedical effects of carboxylated single-wall carbon nanotubes on telomerase and telomeres. Nat Commun. 2012;3:1074.
76. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274-84.
77. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003;3:55-63. (Pubitemid 37328887)
78. Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst. 2005;97:632-42. (Pubitemid 40812627)
79. Smith SC, Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer. 2009;9:253-64.
80. El Touny L, Banerjee P. Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells. Biochem Biophys Res Commun. 2007;361:169-75. (Pubitemid 47103319)
81. Xu J-H, Guo X-Z, Ren L-N, Shao L-C, Liu M-P. KAI1 is a potential target for anti-metastasis in pancreatic cancer cells. World J Gastroenterol. 2008;14:1126-32. (Pubitemid 351325016)
82. Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett. 2007;257:16-35.
83. Matos MA, Tannuri U, Guarniero R. The effect of zoledronate during bone healing. J Orthop Traumatol. 2010;11:7-12.
84. Wu L, Zhu L, Shi W-H, Zhang J, Ma D, Yu B. Zoledronate inhibits the proliferation, adhesion and migration of vascular smoothmuscle cells. Eur J Pharmacol. 2009;602:124-31.
85. Hynes NE. H. a Lane. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-54.
86. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550-65. (Pubitemid 32197693)
87. Weigelt B, Peterse JL. L.J. van 't Veer. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591-602. (Pubitemid 41081385)
88. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463-75.
89. Weinberg RA. Perspectives in cancer research oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 1989;49:3713-21. (Pubitemid 19197385)
90. Baguley B. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 2003;4:141-8. (Pubitemid 36322304)
91. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-39. (Pubitemid 37328908)
92. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer. 2008;8:880-7.
93. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with largemolecules. Nat Rev Clin Oncol. 2009;6:507-18.
94. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J. R. a Smith, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835-44. (Pubitemid 44480537)
95. Ronca R, Sozzani S, Presta M, Alessi P. Delivering cytokines at tumor site: the immunocytokine-conjugated anti-EDB-fibronectin antibody case. Immunobiology. 2009;214:800-10.
96. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5:436-46. (Pubitemid 40791486)
97. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol. 2009;6:395-404.
98. Reinacher-Schick A, Pohl M, Schmiegel W. Drug insight: antiangiogenic therapies for gastrointestinal cancers - focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol. 2008;5:250-67. (Pubitemid 351637911)
99. Cragg GM, Newman DJ. Nature: a vital source of leads for anti-cancer drug development. Phytochem Rev. 2009;8:313-31.
100. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-74. (Pubitemid 43093963)
101. Legg JA, Herbert JMJ, Clissold P, Bicknell R. Slits and roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis. 2008;11:13-21.
102. Koch AW, Mathivet T, Larrivée B, Tong RK, Kowalski J, Pibouin-Fragner L, et al. Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell. 2011;20:33-46.
103. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220-8.
104. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-99. (Pubitemid 39070849)
105. Guaman-Ortiz LM, Giansanti V, Dona F, Scovassi I. Pharmacological effects of PARP inhibitors on cancer and other diseases. Curr Enzym Inhib. 2011;7:244-58.
106. Davar D, Beumer J, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem. 2012;19:3907-21.
107. Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat. 2009;12:153-6.
108. Jagtap P, Szabó C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005;4:421-40. (Pubitemid 40704125)
109. Annunziata C, O'Shaughnessy J. PARP as a novel therapeutic target in cancer. Clin Cancer Res. 2011;16:4517-26.
110. Begg AC. F. a Stewart, C. Vens. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11:239-53.
111. D. Davidson, Y. Wang, R. Aloyz, L. Panasci. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Invest. New Drugs. (2013) 1-8.
112. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287-94.
113. Ekblad T, Camaioni E, Schüler H, Macchiarulo A. PARP inhibitors: polypharmacology versus selective inhibition. FEBS J. 2013;280:3563-75.
114. Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in cancer. Front Oncol. 2013;3:1-11.
115. Do K, Chen A. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res. 2013;19:977-84.
116. Nijman SMB, Friend SH. Potential of the synthetic lethality principle. Science. 2013;342:809-11.
117. De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol. 2013;3:228.
118. Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol. 2010;7:508-19.
119. Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol. 2013;3:237.
120. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis. 2006;21:3-9. (Pubitemid 43288730)
121. Matsuoka S. B. a Ballif, A. Smogorzewska, E.R. McDonald, K.E. Hurov, J. Luo, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160-6.
122. Helleday T, Petermann E, Lundin C, Hodgson B. R. a Sharma. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193-204. (Pubitemid 351301852)
123. Yang D, Halaby M, Li Y, Hibma JC, Burn P. Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration. Drug Discov Today. 2011;16:332-8.
124. A. Nadkarni, M. Shrivastav, A.C. Mladek, P.M. Schwingler, P.T. Grogan, J. Chen, et al. ATMinhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J. Neurooncol. (2012).
125. Rainey M, Charlton M, Stanton R, Kastan M. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008;68:7466-74.
126. Fukasawa K. Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer. 2007;7:911-24. (Pubitemid 350165854)
127. Kops GJPL. B. a a Weaver, D.W. Cleveland. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5:773-85. (Pubitemid 41400777)
128. Zhivotovsky B, Kroemer G. Apoptosis and genomic instability. Nat Rev Mol Cell Biol. 2004;5:752-62. (Pubitemid 39208184)
129. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008;14:1639-48. (Pubitemid 351471713)
130. Kitzen JJEM. M.J. a de Jonge, J. Verweij. Aurora kinase inhibitors. Crit Rev Oncol Hematol. 2010;73:99-110.
131. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004;10:262-7. (Pubitemid 38667616)
132. Keen N, Taylor S. Mitotic drivers-inhibitors of the Aurora B kinase. Cancer Metastasis Rev. 2009;28:185-95.
133. Fiaschi T, Chiarugi P. Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol. 2012;2012:762825.
134. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12:685-98.
135. Aft RL, Zhang FW, Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer. 2002;87:805-12. (Pubitemid 35178760)
136. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9:447-64.
137. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg effect" and a pivotal target for effective therapy. Semin Cancer Biol. 2009;19:17-24.
138. Cohen S, Flescher E. Methyl jasmonate: A plant stress hormone as an anti-cancer drug. Phytochemistry. 2009;70:1600-9.
139. Raviv Z, Cohen S, Reischer-Pelech D. The anti-cancer activities of jasmonates. Cancer Chemother Pharmacol. 2013;71:275-85.
140. Vander Heiden M, Christofk H, Schuma E, Subtelny AO, Sharfi H, Harlow E, et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol. 2010;79:1118-24.
141. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med. 2011;89:205-12.
142. Goldberg MS. P. a Sharp. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med. 2012;209:217-24.
143. Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene. 2011;30:4297-306.
144. Iqbal MA, Bamezai RNK. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS One. 2012;7:e36764.
145. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85-95.
146. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010;107:2037-42.
147. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004;305:200-5. (Pubitemid 38886725)
148. Sharma SV, Settleman J. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". Biochem Pharmacol. 2010;80:666-73.
149. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83-117.
150. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer. 2006;6:613-25. (Pubitemid 44140859)
151. Katz JB, Muller AJ, Prendergast GC. T-cell tolerance and tumoral immune escape. Immunol Rev. 2008;2008(222):206-21.
152. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 2008;27:3889-900. (Pubitemid 351913639)
153. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237-51.
154. Yared J, Kimball A, Baer MR, Bahrain H, Auerbach M. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13:253-7.
155. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317-27.
156. A.E. Moran, M. Kovacsovics-Bankowski, A.D. Weinberg. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. (2013) 1-8.
157. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:4371-7.
158. Houot R, Kohrt H, Goldstein MJ, Levy R. Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer Metastasis Rev. 2011;30:97-109.
159. Peggs KS. S. a Quezada, C. a Chambers, A.J. Korman, J.P. Allison. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717-25.
160. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-99.
161. Fried B, Reddy A, Mayer D. Helminths in human carcinogenesis. Cancer Lett. 2011;305:239-49.
162. Aggarwal BB. R. V Vijayalekshmi, B. Sung. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15:425-30.
163. Kundu J, Surh Y. Breaking the relay in deregulated cellular signal transduction as a rationale for chemoprevention with anti-inflammatory phytochemicals. Mutat Res. 2005;591:123-46. (Pubitemid 41654844)
164. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349-61. (Pubitemid 351595216)
165. Greene ER, Huang S, Serhan CN, Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat. 2011;96:27-36.
166. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181-93.
167. Cuzick J, Otto F. J. a Baron, P.H. Brown, J. Burn, P. Greenwald, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501-7.
168. Ben-Baruh A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38-52.
169. Galzi J-L, Hachet-Haas M, Bonnet D, Daubeuf F, Lecat S, Hibert M, et al. Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications. Pharmacol Ther. 2010;126:39-55.
170. Trotta T, Costantini S, Colonna G. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design. Mol Immunol. 2009;47:332-9.
171. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361-71.
172. Lin Y, Bai L, Chen W, Xu S. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010;14:45-55.
173. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70:i104-8.
174. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904-10.
175. Shen H-M, Tergaonkar V. NFjB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis. 2009;14:348-63.
176. Brown ER. K. a Charles, S. a Hoare, R.L. Rye, D.I. Jodrell, R.E. Aird, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol. 2008;19:1340-6.
177. Zidi I, Mestiri S, Bartegi A, Ben Amor N. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27:185-98.
178. Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 2010;87:401-6.
179. Olivier S, Robe P, Bours V. Can NF-kB be a target for novel and efficient anti-cancer agents ? Biochem Pharmacol. 2006;72:1054-68. (Pubitemid 44465845)
180. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5:297-309. (Pubitemid 40488635)
181. Emadi A, Gore SD. Arsenic trioxide - an old drug rediscovered. Blood Rev. 2010;24:191-9.
182. Coussens LM, Zitvogel L. a. K. Palucka. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339:286-91.
183. Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs. 2009;20:880-92.
184. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J. Terpenoids: natural inhibitors of NF-kappaB signaling with antiinflammatory and anticancer potential. Cell Mol Life Sci. 2008;65:2979-99.
185. J. Shortt, a K. Hsu, R.W. Johnstone. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. (2013) 1-12.